Among the plethora of environmental antigens to which human subjects are regularly exposed, only a few display a high propensity to act as allergens triggering type I allergic diseases (ie, T~H~2-biased immune responses characterized by aberrant levels of IgE production). Allergens encompass a diverse group of molecules that address innate immune pathways through protease activity, lipid binding, engagement of pattern recognition receptors, molecular mimicry of Toll-like receptor signaling molecules, or provision of complex carbohydrate structures.[@bib1] Interestingly, allergens can be found in only 2% of all known protein families, and the distribution of allergens is highly biased toward a few of these protein families.[@bib2] Hence it is obvious to speculate that beyond the abovementioned particular intrinsic biological functions, common structural and biochemical determinants of allergenicity might exist that have yet to be determined.

Bet v 1.0101 (Bet v 1), the major allergen found in birch pollen, belongs to family 10 of the plant pathogenesis-related proteins and is the most intensely studied allergen. Its structure,[@bib3] as well as its T- and B-cell epitopes,[@bib4], [@bib5], [@bib6], [@bib7] are known. The hydrophobic cavity of Bet v 1 has been demonstrated to bind a variety of ligands,[@bib8] including pollen-derived quercetin,[@bib9] an iron-binding catechol derivative. Recently, the apo-form of Bet v 1 (loaded with catechol in the absence of iron) has been suggested to have a T~H~2-promoting potential.[@bib10] Moreover, binding of the model ligand deoxycholate has been implicated in compaction and rigidification of the Bet v 1 molecule[@bib11] and stabilization of its conformational epitopes.[@bib12] These data indicate that the structural stability of Bet v 1 represents a determinant of its allergenicity.

To investigate solely the effect of conformational stability on the sensitization capacity of Bet v 1, we used an approach lacking any immunologically relevant confounders, such as artificial ligands or immunization with adjuvants. We generated variants of Bet v 1 with enhanced fold stability by means of introducing 1, 2, 3, or 4 sequential point mutations. Mutations were selected based on a recently developed *in silico* approach that uses normalized knowledge-based energy potentials for predicting the influence of single point mutations or combinations thereof on protein stability.[@bib13] In-depth comparison of the Bet v 1 mutants with the wild-type protein revealed increased thermal and chemical stability, reduced backbone flexibility, and enhanced resistance to degradation by proteases. In the absence of adjuvants, the wild-type molecule induced only marginal immune responses, whereas the stabilized mutants triggered significant serum IgG and IgE titers and IL-4 production. Allergenicity and immunogenicity of the mutant proteins strongly correlated with protease resistance at slightly acidic pH and efficient proteolytic processing at lower pH, resembling the early and late endosomal environment, respectively. Based on our findings, we propose that differential, pH-dependent fold stability in the early versus late endosomal compartment is a protein-inherent key determinant of allergenicity.

Methods {#sec1}
=======

Expression and purification of recombinant proteins {#sec1.1}
---------------------------------------------------

Wild-type Bet v 1 and the 4 mutants were expressed from pET28b constructs in *Escherichia coli* strain BL21 Star (DE3; Invitrogen, Carlsbad, Calif), as described in the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}.

Protein characterization and structure determination {#sec1.2}
----------------------------------------------------

Protein folding in solution and thermal and chemical denaturation were monitored by using differential scanning calorimetry (DSC), circular dichroism (CD), and Fourier transform infrared spectroscopy (FTIR). The monomeric state was measured by using size exclusion chromatography coupled to multiangle light scattering (SEC-MALS). Structure was determined by means of x-ray crystallography. Protein flexibility was assessed by using molecular dynamics simulations, nuclear magnetic resonance (NMR) spectroscopy, and hydrogen/deuterium exchange. These methods are described in detail in the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository.

Mice and immunizations {#sec1.3}
----------------------

Female 6- to 10-week-old BALB/c mice were obtained from Charles River Laboratories (Sulzfeld, Germany) and maintained at the animal facility of the University of Salzburg according to local guidelines for animal care. Animal experiments were approved by the Austrian Ministry of Science (permit no. BMWFW-66.012/0008-WF/II/3b/2014). Mice (n = 5) were immunized 5 times with 20 μg of Bet v 1 or one of the mutant proteins in sterile PBS by means of intradermal injection into the ear pinnae on days 0, 14, 28, 42, and 81. A total volume of 80 μL was divided between the 2 sides. Blood samples were taken at regular intervals. Mice were killed on day 88 for preparation of splenocytes.

Antibodies and cytokines {#sec1.4}
------------------------

Levels of IgG~1~ and IgG~2a~ subclass antibodies in sera measured on day 88 were evaluated by using a luminometric ELISA[@bib14] at serum dilutions of 1:300 and 1:100, respectively, lying within the linear range of the assay.

The IgE cross-linking capacity of the mutant proteins was assessed by using a β-hexosaminidase release assay, as described in the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository.

The amount of cell-bound IgE was measured by using a basophil activation test, as previously described.[@bib15] Heparinized whole blood taken on day 84 of the experimental schedule was diluted 1:2 with RPMI 1640 and incubated with 10 ng/mL Bet v 1 or the respective mutant or left untreated as a control for 2 hours at 37°C and 5% CO~2~. Cells were washed, and surface staining was performed with anti-CD200 R (clone OX110; eBioscience, San Diego, Calif), anti-IgE (clone RME-1; BioLegend, San Diego, Calif), anti-CD4 (clone GK1.5, BioLegend), and anti-CD19 (clone 6D5, BioLegend). Subsequently, cells were washed with PBS/1% BSA/2 mmol/L EDTA and analyzed on a FACSCanto II flow cytometer (BD Biosciences, San Jose, Calif).

Splenocytes from immunized mice were prepared and cultured, as previously described,[@bib14] in the presence of Bet v 1 or the mutants (20 μg/mL) to determine the number of IL-4 and IFN-γ producers per 2 × 10^5^ cells by using ELISpot (Millipore, Bedford, Mass).

Endolysosomal degradation simulations {#sec1.5}
-------------------------------------

Endolysosomal degradation assays were performed, as previously described.[@bib16] Briefly, 5 μg of protein substrates (Bet v 1 and Bet_mut1 to Bet_mut4) was mixed with 8 μg of isolated microsomal fraction from the JAWS II cell line in 50 mmol/L citrate buffer (pH 5.9, pH 5.2, or pH 4.5) and 2 mmol/L dithiothreitol.

The pool of peptides generated from Bet v 1 and the mutants in the degradation assay at pH 5.2 and pH 4.5 was assessed by using mass spectrometry with a Q-Exactive Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, Mass) with nanoelectrospray and nano-HPLC (Dionex Ultimate 3000, Thermo Fisher Scientific). For details, see the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository.

Uptake and processing of Bet v 1 and Bet variants by monocyte-derived dendritic cells and stimulation of Bet v 1--specific T cells {#sec1.6}
----------------------------------------------------------------------------------------------------------------------------------

Experiments involving human cells were conducted in accordance with the guidelines of the World Medical Association\'s Declaration of Helsinki. Samples of human origin were obtained from blood donations, and use of residual cells was approved by the Institutional Review Board of Upper Austria. Monocyte-derived dendritic cells (moDCs) were generated from buffy coats from healthy anonymous donors (provided by the Red Cross Transfusion Service of Upper Austria), as described in the [Methods](#appsec1){ref-type="sec"} section in this article\'s Online Repository. For investigating the uptake kinetics of Bet v 1 and its variants, moDCs were incubated with DyLight488-labeled proteins at 20 μg/mL for 30, 60, and 120 minutes, respectively, and uptake was determined by means of flow cytometry.

moDCs from HLA-DRB1\*07:01--restricted donors were incubated for 30 to 480 minutes with Bet v 1 or the mutants at 20 μg/mL. Subsequently, moDCs were washed and cocultured with Jurkat T cells expressing a Bet v 1~142-153~--specific T-cell receptor and harboring a human IL-2 promoter/enhancer controlling luciferase expression[@bib17] for 6 hours. Cells were lysed in 50 μL of lysis buffer (100 mmol/L potassium phosphate, 0.1% Triton X-100, and 1 mmol/L dithiothreitol), and luciferase activity was measured in a Tecan Infinite 200 Pro microplate reader with 50 μL of luciferase substrate (Promega, Madison, Wis).

Results {#sec2}
=======

Generation of Bet v 1 mutants with increased fold stability {#sec2.1}
-----------------------------------------------------------

We have previously demonstrated the use of knowledge-based potentials for generating destabilized allergens.[@bib13] Knowledge-based potentials are used to investigate sequence-structure relations in known 3-dimensional protein structures, describing the interactions between amino acid residues and the interaction of the residues with the surrounding solvent. By using this method, a *z* score is generated, which indicates either stabilization (decrease of *z* score) or destabilization (increase of *z* score).[@bib18] Here we applied this approach to generate fold-stabilized mutants of Bet v 1. By using *in silico* permutation of every amino acid, mutants were selected, which predicted the strongest stabilizing effect. The immunodominant region of Bet v 1 (Bet~142-156~)[@bib4] was excluded from the mutation process to avoid changes in immunogenicity because of destruction of T-cell epitopes. Likewise, solvent-exposed residues (accessible surface area \>30%), which can contribute to IgE binding,[@bib19] were left untouched. In an iterative manner, up to 4 point mutations were introduced, resulting in the generation of Bet_mut1, Bet_mut2, Bet_mut3, and Bet_mut4 ([Table I](#tbl1){ref-type="table"}). All selected mutations were located in regions representing minor T-cell epitopes recognized by only 3.5% to 8.8% of allergic donors[@bib4] or 0% to 3.3% of sensitized BALB/c mice,[@bib20] respectively.

Proteins were expressed tag-free in *E coli* and purified by using hydrophobic interaction chromatography and anion exchange chromatography, followed by an endotoxin removal step. The final purity was greater than 99%, as determined by using SDS-PAGE (see [Fig E1](#appsec1){ref-type="sec"}, *A*, in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}), and preparations were essentially LPS free (\<0.4 pg/μg protein). Identity was confirmed by means of mass spectroscopy (see [Fig E1](#appsec1){ref-type="sec"}, *B*), and the correct conformation (see [Fig E1](#appsec1){ref-type="sec"}, *C*) and monomeric state (see [Fig E1](#appsec1){ref-type="sec"}, *D*) of the proteins were demonstrated by using CD spectroscopy and SEC-MALS, respectively.

A more detailed analysis with x-ray crystallography showed that the 3-dimensional structures of the mutants were remarkably similar to that of the wild-type protein. The superimposition of the crystal structures of the quadruple mutant Bet_mut4 with Bet v 1 revealed that the overall fold is identical, with a total root-mean-square deviation of 0.7 Å ([Fig 1](#fig1){ref-type="fig"}).

Overall fold identity was also confirmed by using an IgE-binding assay with rat basophil leukemia (RBL) cell degranulation (see [Fig E2](#appsec1){ref-type="sec"}, *A*, in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}), which demonstrated that all mutants had retained the capacity to cross-link cell-bound IgE. This indicates that surface epitopes were mainly left intact by the introduction of stabilizing mutations. Degranulation was slightly lower in the mutants compared with the wild-type protein, suggesting the possibility of subtle changes to conformational epitopes. Likewise, an RBL assay and a basophil activation test were performed with human sera from donors with birch pollen allergy. All mutant proteins showed very similar IgE-binding capacity compared with the wild-type Bet v 1 (see [Fig E2](#appsec1){ref-type="sec"}, *B* and *C*). This confirms that the surface structure of the recombinant mutant proteins resembles that of naturally occurring Bet v 1.

Introduction of the point mutations effectively enhanced the thermal and chemical fold stability of Bet v 1, as assessed by using CD spectroscopy and DSC. All proteins were analyzed in phosphate buffer at pH 7.4. The first mutation (D69I) was sufficient to enhance chemical stability (ie, the amount of urea required to induce 50% unfolding of the protein) from 2.8 to 5.2 mol/L urea, corresponding to a shift in Gibbs-free energy (ΔG) of approximately 4 to 5 kcal/mol ([Fig 2](#fig2){ref-type="fig"}, *A*). Interestingly, the additional mutations showed no additive effect. This was confirmed by results of thermal denaturation analysis in which D69I induced a shift of greater than 20°C in melting temperature ([Fig 2](#fig2){ref-type="fig"}, *B-D*). Inclusion of the P90L mutation in mutants 3 and 4 led to evident aggregation at temperatures of greater than 80°C, as indicated by the distorted baseline after the transition peak (marking the transition from native to unfolded state) in the DSC diagram ([Fig 2](#fig2){ref-type="fig"}, *C*). Despite this complexity, the same pattern of stabilization for these mutants over wild-type protein was observed at different protein concentrations (0.15-0.5 mg/mL; [Fig 2](#fig2){ref-type="fig"}, *C*). In the case of mutant 4, there was also an additional reproducible decrease in baseline before the transition peak of unknown origin. A similar stabilization for the mutants of approximately 5 kcal/mol could be estimated from the DSC data. Thermal denaturation was not repeatable, indicating a nonequilibrium mechanism and thus preventing detailed interpretation of the DSC data. However, the data indicated the exact same pattern and magnitude of significant fold stabilization seen in chemical and thermal denaturation by using CD ([Fig 2](#fig2){ref-type="fig"}, *A* and *B*).

Increased fold stability enhances allergenicity and immunogenicity {#sec2.2}
------------------------------------------------------------------

BALB/c mice were immunized intradermally into the ear pinnae with the respective protein dissolved in PBS to assess immune response in the absence of immunomodulatory confounders, such as adjuvants. As shown in [Fig 3](#fig3){ref-type="fig"}, *A*, Bet v 1 was nonimmunogenic in this adjuvant-free setting. In contrast, mutants 2, 3, and 4 induced significantly higher titers of Bet v 1--specific IgG~1~ and low levels of IgG~2a~. Notably, antibody responses against the homologous mutant protein in the individual groups (with few exceptions) closely resembled those observed against the wild-type protein, underscoring the high degree of conformational homology of the mutant proteins (see [Fig E3](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}). Introducing fold-stabilizing mutations not only increased the immunogenicity in terms of IgG~1~ production but also resulted in the formation of allergen-specific IgE, which was mainly cell bound ([Fig 3](#fig3){ref-type="fig"}, *B*). This was most prominent for mutant 4, which also induced high levels of IL-4--secreting splenocytes ([Fig 3](#fig3){ref-type="fig"}, *C*) and detectable levels of free, allergen-specific serum IgE ([Fig 3](#fig3){ref-type="fig"}, *B*). No significant levels of IFN-γ were detected in any group ([Fig 3](#fig3){ref-type="fig"}, *C*). In summary, allergenicity and immunogenicity were increased with every additional introduction of a fold-stabilizing mutation, with the most striking effects observed for the mutant harboring 4 point mutations.

Fold-stabilizing mutations reduce flexibility {#sec2.3}
---------------------------------------------

The data shown above clearly point to an effect of the number of fold-stabilizing mutations on allergenicity and immunogenicity. However, none of the 4 mutants differed in their thermal stability. Because the flexibility of a protein is known to influence the accessibility of lysosomal proteases and hence presentation of peptides on MHC molecules,[@bib21], [@bib22] we studied the molecular dynamics of the wild-type molecule and the 4 mutants with simulations over 100 ns for each system by using AMBER12.[@bib23] To capture residue-wise flexibility, we calculated B factors for Cα atoms from the resulting conformational ensembles of the proteins after global alignment. Furthermore, we calculated dihedral entropies based on the distributions of torsion angles of the protein backbone.[@bib24] Simulation data indicate that all systems are rigidified considerably by the introduction of the point mutations. Local dynamics of residues around the mutation sites are especially reduced, thus pointing to a gain in stability (see [Fig E4](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}).

To experimentally confirm changes in flexibility, we used hydrogen/deuterium exchange measurement with FTIR. As shown in [Fig 4](#fig4){ref-type="fig"}, *A*, all mutants showed an overall slower exchange rate compared with the wild-type protein, indicating reduced molecular dynamics. However, at this much slower time scale, Bet_mut4 turned out to be the most rigid molecule. These findings could be further substantiated by using relaxation dispersion NMR,[@bib25] which confirmed the substantial decrease in flexibility on the microsecond-to-millisecond time scale in Bet_mut4 ([Fig 4](#fig4){ref-type="fig"}, *D*) compared with Bet_mut1 ([Fig 4](#fig4){ref-type="fig"}, *C*) and the wild-type molecule ([Fig 4](#fig4){ref-type="fig"}, *B*).

Protease-mediated degradation is reduced in fold-stabilized mutants {#sec2.4}
-------------------------------------------------------------------

To assess whether the increased thermal stability and reduced flexibility of fold-stabilized mutants indeed affects the degradation of the protein in the endolysosome, we performed a degradation assay using microsomal enzyme preparations of JAWS II cells at different pH values, thus simulating the pH decrease during maturation from early endosome to late endolysosome.

The degradation assay revealed no detectable proteolysis of Bet v 1 at pH 5.9, which might reflect an intrinsic stability of wild-type Bet v 1, as well as a reduced proteolytic activity at this pH, but a complete degradation at a pH of 5.2 within 12 hours, as assessed by using SDS-PAGE ([Fig 5](#fig5){ref-type="fig"}, *A*). In contrast, all mutants were resistant to proteolysis under these conditions. However, at lower pH, Bet_mut4 suddenly became susceptible to degradation. Interestingly, this change in protease susceptibility at lower pH correlated with a reduced thermal stability, as assessed by using CD spectroscopy (monitoring protein unfolding; [Fig 5](#fig5){ref-type="fig"}, *B*) and FTIR (here used for monitoring aggregation by unfolding; [Fig 5](#fig5){ref-type="fig"}, *C*). Analysis of the resulting peptides with liquid chromatography coupled to mass spectrometry revealed that processing of Bet v 1 progresses from the N- and C-termini of the molecule to the inner core. Proteolysis of the mutants followed a similar pattern, although at lower speed ([Fig 5](#fig5){ref-type="fig"}, *D*). No differences in the population of generated peptides were observed between Bet v 1 and its variants, indicating that no cleavage sites were introduced or removed by the inserted point mutations (full degradation patterns at different pH can be found in [Figs E5-E14](#appsec1){ref-type="sec"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0035}). It must be taken into account that these degradation processes will happen much faster *in vivo* because of the extremely high local concentration of proteolytic enzymes in the endolysosome. For example, cathepsin concentrations in lysosomes can well exceed 1 mmol/L,[@bib26] which is at least 10^6^-fold higher compared with the concentrations used in our *in vitro* assays. Nevertheless, the assay qualitatively resembles the course of *in vivo* processing because the full proteolytic machinery is present in the endolysosomal preparations.[@bib16]

Presentation of the immunodominant epitope Bet~142-153~ is enhanced in Bet_mut4 {#sec2.5}
-------------------------------------------------------------------------------

Uptake of Bet v 1 and the mutant proteins by moDCs was monitored by pulsing cells with DyLight488-labeled proteins. Flow cytometric analysis revealed no differences with regard to the percentage of antigen-positive cells ([Fig 6](#fig6){ref-type="fig"}, *A*) and their mean fluorescence intensity ([Fig 6](#fig6){ref-type="fig"}, *B*).

To rule out that the increase in immunogenicity observed for Bet_mut2-4 might be due to the generation of new T-cell epitopes by the mutation process, we investigated the activation of a transgenic HLA-DRB1\*07:01--restricted Jurkat T-cell line specific for the immunodominant peptide Bet~142-153~. moDCs from a HLA-DRB1\*07:01--positive donor were cultured with Bet v 1 and the mutant proteins for 30 to 1440 minutes before adding Jurkat cells expressing the specific T-cell receptor. Six hours later, T-cell activation was determined by measuring a luciferase reporter under control of the IL-2 promoter.[@bib17]

Although antigen uptake was similar for the wild-type protein and the 4 mutants, Bet_mut4 (and, to a lesser degree, Bet_mut3) showed enhanced T-cell stimulatory capacity, especially at the early time points ([Fig 6](#fig6){ref-type="fig"}, *C*). This indicates that larger amounts of the immunodominant peptide are presented by moDCs when processing the fold-stabilized mutants Bet_mut3 and Bet_mut4. Notably, both variants were highly stable at a pH of greater than 5.2 while becoming destabilized at lower pH. These *in vitro* data from human cells remarkably resemble *in vivo* data from mouse experiments ([Fig 3](#fig3){ref-type="fig"}), supporting a mechanism for immunogenicity being dependent on high stability in the early endosome and protease susceptibility in the late endosome.

Discussion {#sec3}
==========

Recent concepts link protein-intrinsic features, such as protease activity, molecular mimicry, and ligand binding, to allergic immune responses.[@bib1], [@bib27] However, there are very few data dealing with the role of protein fold stability concerning induction of a T~H~2 immune response.[@bib28]

Antigen processing and presentation consists of several steps, including uptake/internalization of proteins, reduction of disulfide bonds and unfolding, endosomal/lysosomal proteolysis, and loading of peptides onto MHC class II molecules. Because proteases preferentially degrade proteins in a denatured state, unfolding represents an indispensable step for intracellular processing of protein antigens.[@bib29] Interestingly, modifying proteins to increase their stability has produced contradictory results. Some studies reported decreased T-cell or antibody responses when immunizing with stabilized antigens,[@bib30], [@bib31], [@bib32] whereas others could correlate increased stability/slower proteolytic degradation of internalized antigens with prolonged retention of antigen in secondary lymphoid organs and enhanced presentation of T-cell epitopes[@bib33] and increased humoral and long-lasting cellular immunity.[@bib34], [@bib35], [@bib36] Reduced susceptibility to degradation might not only enhance the preservation of CD4^+^ T-cell epitopes but also prolong the persistence of the proteins for sustained processing and presentation by DCs and even allow for transfer of intact antigen to B cells.[@bib37], [@bib38]

In the present study we used an unbiased computational approach and generated Bet v 1 mutants with a striking increase in their fold stability while preserving the natural conformation of the wild-type molecule. The stabilizing effects of the mutations D69I, K97I, and G26L can be explained by the local environment within the crystal structure ([Fig 1](#fig1){ref-type="fig"}, *A*). Contrasting the original Asp69, the isoleucine matches the hydrophobic nature of the cavity formed by Ile56, Phe58, Val67, Tyr83, and Val85. Additionally, several solvent molecules were released in the mutated structure compared with the wild-type structure, leading to an entropically driven stabilization ([Fig 1](#fig1){ref-type="fig"}, *B*). A similar effect was also observed for K97I, which is located on the protein surface. Furthermore, the conformation of the neighboring residue Glu95 was slightly different, thus stabilizing the hydrophobic residue with its aliphatic chain ([Fig 1](#fig1){ref-type="fig"}, *C*). The mutation P90L induced an alternative conformation in the main chain of the surrounding residues as indicated, which is more difficult to interpret with respect to its effect on stability ([Fig 1](#fig1){ref-type="fig"}, *D*). Mutation G26L fills an internal hydrophobic cavity formed by Phe21, Ile22, and Phe30 ([Fig 1](#fig1){ref-type="fig"}, *E*).

Taken together, all the introduced mutations were aliphatic residues oriented toward the hydrophobic cavity of Bet v 1 ([Fig 1](#fig1){ref-type="fig"}). These mutations act like anchors responsible for the dramatic rigidification of the molecular structure predicted by molecular dynamics (see [Fig E4](#appsec1){ref-type="sec"}) and further confirmed by hydrogen/deuterium exchange and NMR ([Fig 4](#fig4){ref-type="fig"}). Interestingly, binding of model ligands to the hydrophobic cavity of Bet v 1 has been shown to result in rigidification[@bib11] and reduced proteolytic degradation[@bib12] of the protein, which is similar to what we observed in our experimental system. Ligand binding to Bet v 1 has also been linked to its allergenic potential.[@bib10], [@bib12] However, in our ligand-free system we could demonstrate for the first time that not the ligand itself but the change of the structural stability of the protein represents the underlying general principle of immunomodulation. Also, we can exclude aggregation[@bib39] as a biologically relevant mechanism for the observed effects because aggregation events only took place at temperatures of greater than 60°C ([Fig 2](#fig2){ref-type="fig"}, *C*).

In a recent publication Ohkuri et al[@bib31] have suggested that a certain energy threshold exists that solely defines whether a protein is immunogenic. Our data clearly indicate that this is an oversimplification not reflecting the complex effect of pH-dependent protein stability in the course of degradation, starting in the early and moving to the late endosomal compartment. It has to be taken into account that antigens face a continuous decrease in pH from 7.4 (in the extracellular environment) to 4.0 in terminal lysosomes. Indeed, we could demonstrate that the mutant proteins Bet_mut1 to Bet_mut4 show similarly high stability at neutral pH; however, they strongly differ in their stability and proteolytic susceptibility at acidic pH, and this affects their immunogenicity. Interestingly, the dominant T-cell epitope of Bet v 1 was found to be highly susceptible to degradation independent of pH or time point in *in vitro* degradation assays ([Fig 5](#fig5){ref-type="fig"}, *D*, and see [Figs E5-E14](#appsec1){ref-type="sec"}); indeed, we never identified the full-length peptide Bet~142-153~. This suggests that *in vivo* this epitope has to be protected from proteolytic degradation, possibly by binding to class II molecules.[@bib40]

On the basis of these results, we propose a model ([Fig 7](#fig7){ref-type="fig"}) in which immunogenicity/allergenicity is determined by a pH-dependent balance of protease accessibility of allergens, resulting in optimal loading of MHC class II. It is known that the early endosome (approximately pH 6) and the terminal lysosome (approximately pH 4.0-4.5) are poor in MHC class II, whereas late endosomes (approximately pH 4.5-5.5) display high quantities of MHC class II organized in multivesicular bodies.[@bib41] The poor immunogenicity of Bet v 1 after vaccinating mice in the absence of adjuvant can be explained by the low proteolytic stability of the molecule along the endosome maturation, a process highly conserved between species.[@bib42], [@bib43] This results in low peptide abundance in the late endosome, in which the majority of MHC loading takes place.[@bib41] Interestingly, a similarly low immunogenicity can be observed for Bet_mut1, although it is extremely stable to pH-mediated unfolding. The resulting poor accessibility to proteases leads to the same effect as low proteolytic stability (ie, low peptide abundance in the late endosome and suboptimal MHC loading). In contrast, Bet_mut4 is highly stable at a pH of greater than 5, suggesting that it accumulates during the early endosomal maturation and can then be processed efficiently in the late endosome, where it becomes susceptible to degradation. Our *in vivo* mouse data are further substantiated by *in vitro* data from human moDCs ([Fig 6](#fig6){ref-type="fig"}). Thus the differential stability of Bet_mut4 at different pH values ([Fig 5](#fig5){ref-type="fig"}) results in efficient presentation of T-cell epitopes in the context of MHC-II on human moDCs ([Fig 6](#fig6){ref-type="fig"}) and promotes T~H~2-biased immune responses in mice ([Fig 3](#fig3){ref-type="fig"}).

In summary, our data clearly show that the pH-dependent stability of Bet v 1 is a key factor for allergenicity and immunogenicity *in vivo* and that epitope-specific T-cell activation is highly influenced by the fold stability of the protein. Our results also provide a mechanism for how real-life ligand binding to the hydrophobic cavity of Bet v 1 could render the molecule highly allergenic (ie, by inducing a change in fold stability similar to that observed for Bet_mut4). This has direct implications for the use of recombinant Bet v 1.0101 for allergen-specific immunotherapy because in the absence of a ligand, the recombinant protein might not be optimal in stimulating potent T-cell responses. Thus in addition to increasing the understanding of structural determinants of allergenicity, our findings have broader implications for a rational design of hyperimmunogenic antigens for vaccination, as well as hypoimmunogenic molecules for use as biological agents.Key messages•Fold stability is a key determinant of the sensitizing potential of allergen molecules.•Efficient T~H~2 cell activation requires both an increased stability at the pH of the early endosome and efficient degradation at a lower pH resembling the late endosomal/lysosomal compartment.
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![Crystal structure of the quadruple mutant Bet_mut4 *(blue)* in comparison with Bet v 1 (*gray*, PDB: 4A88). Superimposition of Bet_mut4 with Bet v 1 revealed that the overall fold is conserved. **A,** Mutated residues D69I, K97I, P90L, and G26L are shown as sticks. **B,** An enlarged view of the mutated residue D69I shows that it is stabilized by several hydrophobic residues, including Ile56, Phe58, Val67, Tyr83, and Val85. **C,** The surface-exposed mutation K97I is likely to entropically stabilize the protein by releasing coordinated solvent molecules. **D,** Mutation P90L induced an alternative conformation, as indicated. **E,** Mutation G26L fills a hydrophobic cavity formed by Phe21, Ile22, and Phe30. All mutated residues are shown as *blue sticks* compared with sticks from wild-type Bet v 1 *(gray)*. The electron density map (2F~obs~-F~calc~) is contoured at 1 σ over the mean.](gr1){#fig1}

![Thermal stability of Bet v 1 and mutant proteins 1 to 4 (Bet_mut1-4). **A,** Chemical denaturation was assessed by means of CD spectroscopy, and the fraction of denatured protein *(F*~*denatured*~*)* is displayed. **B** and **C,** Thermal denaturation was measured by using CD (Fig 2, *B*) and DSC (Fig 2, *C*). DSC data for wild-type Bet v 1 and mutants were run at a 60°/h scan rate and at 0.15 mg/mL *(lower traces)* and 0.5 mg/mL *(upper traces)* offset in the *y-axis* for clarity. **D,** Melting points calculated from DSC data.](gr2){#fig2}

![Influence of fold-stabilizing mutations on the immunogenicity and sensitization capacity of Bet v 1. **A,** Bet v 1--specific IgG~1~ and IgG~2a~ titers of BALB/c mice (n = 5) immunized intradermally with the different proteins were measured by using a luminometric ELISA at a serum dilution of 1:300 for IgG~1~ and 1:100 for IgG~2a~. Data are shown as relative light units *(RLU)*. **B,** Bet v 1--specific IgE levels in serum were measured with an RBL degranulation assay, and results are presented as the percentage of total release. Cell-bound IgE was assessed by using a basophil activation test, and data are shown as stimulation indices *(SI)*. **C,** Numbers of IL-4-- and IFN-γ--secreting splenocytes after restimulation with Bet v 1 and the respective mutants were determined by using the ELISpot assay. *SFU*, Spot-forming units. Statistical significance compared with Bet v 1 was assessed by using 1-way ANOVA, followed by the Dunnett *post hoc* test. \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001.](gr3){#fig3}

![**A-D,** Influence of fold-stabilizing mutations on the molecular flexibility of the protein, as indicated by hydrogen deuterium exchange (Fig 4, *A*) and relaxation dispersion NMR (Fig 4, *B-D*). In Fig 4, *B-D*, the 11 residues with the largest backbone amide ^15^N relaxation dispersion profiles are displayed.](gr4){#fig4}

![**A-D,** Proteolytic degradation of Bet v 1 and the mutants Bet_mut1 to Bet_mut4 (Fig 5, *A* and *D*) and their thermal stability (Fig 5, *B* and *C*) at different pH values. Proteolytic degradation was assessed by using 15% SDS-PAGE and Coomassie staining (Fig 5, *A*). Thermal stability was followed by using CD spectroscopy (Fig 5, *B*), and thermally induced aggregation was followed by using attenuated total reflectance FTIR (Fig 5, *C*). FTIR data are presented as the fraction of aggregated protein versus temperature. Protein degradation patterns over time were analyzed by using liquid chromatography--mass spectroscopy (Fig 5, *D*): peptides generated earlier during the proteolytic processing are colored in *white*, whereas peptides that were not detected during the whole experiment (48 hours) were colored in *black*. Amino acid positions are labeled at the top. The immunodominant epitope of Bet v 1 is framed in *green*.](gr5){#fig5}

![**A** and **B,***In vitro* antigen processing and presentation. Uptake of DyLight488-labeled Bet v 1 and Bet_mut1-4 by moDCs. The percentage of positive cells (Fig 6, *A*) and their mean fluorescence intensity (*MFI*; Fig 6, *B*) were analyzed by using flow cytometry. moDCs from HLA-DRB1\*07:01^+^ donors were preincubated with Bet v 1 or Bet_mut1-4 for the indicated time span and subsequently cocultured with Bet~142-153~--specific Jurkat T cells. **C,** Luciferase reporter expression under control of the IL-2 promoter was measured after 6 hours of coculture. Data are shown as means ± SEMs of relative light units *(RLU)* of 2 independent experiments by using 2 different donors.](gr6){#fig6}

![Model for immunogenicity/allergenicity of an allergen depending on differential fold stability at different endosomal pH. During antigen uptake and processing, allergens face a broad range of different pH values, ranging from approximately 7.4 in the extracellular matrix to approximately 4.0 in the terminal lysosome. Proteins with low fold stability in the early endosome are proteolytically processed prematurely, resulting in poor antigen presentation because of low abundance of MHC class II in this compartment ("*blue*" protein). Proteins with high fold stability at low pH ("*black*" protein) remain structurally intact until they reach the terminal lysosome, where again MHC class II levels are low and antigen presentation is inefficient. Only proteins that survive the early endosome but are efficiently processed at a more acidic pH can accumulate in the late endosome, where they are finally degraded and loaded on highly abundant MHC II molecules ("*red*" protein).](gr7){#fig7}

###### 

Bet v 1 mutants used in the study

  Protein    Mutations                Combined *z* score
  ---------- ------------------------ --------------------
  Bet v 1    ---                      −8.34
  Bet_mut1   D69I                     −8.9
  Bet_mut2   D69I, K97I               −9.34
  Bet_mut3   D69I, K97I, P90L         −9.80
  Bet_mut4   D69I, K97I, P90L, G26L   −10.18
